Text size :

AIOM Oncologists, ‘adequate budgets are needed to guarantee access to new treatments’

ADNKRONOS

November 9, 2026

Rome, Nov 9. (Adnkronos Health) – The sustainability of the NHS is a crucial value and a shared responsibility. In oncology, it must translate into the ability to make research progress available to patients, through resource planning consistent with the evolution of treatments. This is the message from the Italian Association of Medical Oncology (AIOM), which draws attention to requests for pharmaceutical expenditure containment addressed to oncology structures and calls for budgets commensurate with care needs. “In recent years, therapeutic opportunities have increased, and for many neoplasms, survival and quality of life have improved. Alongside new therapies that replace previous ones, today we can offer treatments even in clinical situations where, until a few years ago, we had no effective options. More people can therefore receive care and, in various contexts, disease control allows them to continue treatment longer. These are results that health planning must take into account,” AIOM emphasizes.

The growth in oncology spending – a note informs – should be read in light of these changes, along with the high cost of many new therapies. Evaluating it solely against previous years’ spending, imposing reductions even in the face of stable or increasing care activity, without considering the number of patients, new indications, and treatment duration, risks producing unrealistic budget targets not aligned with care needs. “Oncologists must be called upon to answer for the appropriateness of clinical choices – the scientific society highlights –. Spending caps, drug prices, and budgets are defined at their respective institutional and corporate levels. Attributing to professionals the responsibility of compensating, solely through prescription review, for the increase in costs and care needs risks transferring a problem that also requires systemic decisions to the clinical level. The adequacy of the spending cap for drugs purchased by public healthcare companies needs to be reviewed upstream. In the absence of resources consistent with needs, the risk is to ration access to care rather than rationalize spending.”

Appropriateness remains a central commitment in oncology. It means – it reads – identifying the best therapy for the individual, based on scientific evidence, disease characteristics, clinical conditions, and patient preferences, in compliance with the reimbursement indications recognized by the Italian Medicines Agency (AIFA). It also means re-evaluating benefits and toxicities over time, avoiding unnecessary tests and treatments, and discontinuing therapies when they no longer offer a clinical benefit, ensuring continuity of care and supportive care. In the presence of multiple therapeutic alternatives for the same clinical condition, with equal efficacy and tolerability, the cost of treatments is also a selection criterion. “It is through this clinical responsibility, exercised throughout the entire pathway, that we contribute to sustainability – AIOM specifies –. The quality of work of an oncology structure must be evaluated considering appropriateness, outcomes, accessibility, and quality of care, along with the use of resources.”

Jiji Press

Related

Page TOP